TWA
LOGC

TCI Wealth Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

TCI Wealth Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-344
Closed -$2K – 2611
2021
Q3 		$2K Hold
344
– – ﹤0.01% 2210
2021
Q2 		$2K Hold
344
– – ﹤0.01% 2148
2021
Q1 		$3K Buy
+344
New +$2.83K ﹤0.01% 1628

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

TCI Wealth Advisors's LOGC Position: Q4 2021 in Review

TCI Wealth Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2021, closing a stake of 344 shares — an estimated $2K sold.

TCI Wealth Advisors first reported a position in LOGC in Q1 2021 and held it in 3 quarters. The position peaked at $3K in Q1 2021. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

  • TCI Wealth Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • TCI Wealth Advisors sold 344 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2K.
  • TCI Wealth Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • TCI Wealth Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on TCI Wealth Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.